Clinical Challenges: Test Your Knowledge on Recent Advances in DLBCL
Knowledge about the biology of diffuse large B-cell lymphoma (DLBCL) and the number of treatments approved for the disease continues to grow. This three-question quiz will test one aspect from each article in MedPage Today‘s Clinical Challenges series on DLBCL that covered the following: use of bispecific antibodies versus CAR T-cell therapy in the relapsed/refractory […]
New Data on BCMA-Directed Bispecifics in Multiple Myeloma
Promising data on new B-cell maturation antigen (BCMA)-directed bispecific antibodies were presented at the American Society of Clinical Oncology (ASCO) annual meeting. These included results on two investigational products: the phase II LINKER-MM1 study, which showed that linvoseltamab elicited an objective response rate of 71% at the recommended dose of 200 mg for patients with […]
Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis
Patients with diffuse large B-cell lymphoma (DLBCL) who also had pre-existing depression, anxiety, or both had a worse prognosis than those without these pre-existing mental health conditions, according to results from a population-based study. Among over 13,000 patients at a median follow-up of 2 years, the 5-year overall survival (OS) rate was 27% for patients […]
CAR-T Therapy Effective in Youngest Kids With ALL
The use of tisagenlecleucel (Kymriah) in children younger than 3 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) was as effective, and safe, in a retrospective cohort study as it was previously seen to be for older children in the ELIANA trial. In an analysis of 38 patients – most of […]
Bispecific Antibody Shows Promise in R/R Multiple Myeloma
Teclistamab, a bispecific antibody that binds B-cell maturation antigen (BCMA) and CD3 to redirect T cells to multiple myeloma cells, showed promising efficacy in patients with relapsed or refractory disease, according to results from a phase I study. Forty patients received the recommended phase II dose of subcutaneous teclistamab, which led to an overall response […]